In hematological malignancies, melatonin can inhibit the proteasome, which is closely related to the regulation of major signal transduction proteins, including p53, NF-κB, caspase-3/9, apoptosis factors BAX and BIM, and anti-apoptotic factors BCL-2, TRAIL, nuclear factor erythroid 2-related factor 2 (NRF2), and β-catenin (111). Here, NFE2L2 is linked to hematologic disorder.